97 related articles for article (PubMed ID: 10652624)
21. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites.
Gervasi F; Lo Verso R; Giambanco C; Cardinale G; Tomaselli C; Pagnucco G
Ann N Y Acad Sci; 2004 Dec; 1028():457-62. PubMed ID: 15650271
[TBL] [Abstract][Full Text] [Related]
23. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a membrane-associated glycoprotein complex implicated in cell adhesion to fibronectin.
Hasegawa T; Hasegawa E; Chen WT; Yamada KM
J Cell Biochem; 1985; 28(4):307-18. PubMed ID: 4055919
[TBL] [Abstract][Full Text] [Related]
25. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
26. Endogenous pyrogen production by Hodgkin's disease and human histiocytic lymphoma cell lines in vitro.
Bodel P; Ralph P; Wenc K; Long JC
J Clin Invest; 1980 Feb; 65(2):514-8. PubMed ID: 6985918
[TBL] [Abstract][Full Text] [Related]
27. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
28. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
29. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
30. A factor from plasma-derived human serum that inhibits the growth of the mammary cell line MCF-7: characterization and purification.
Dell'Aquila ML; Pigott DA; Bonaquist DL; Gaffney EV
J Natl Cancer Inst; 1984 Feb; 72(2):291-8. PubMed ID: 6582317
[TBL] [Abstract][Full Text] [Related]
31. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas.
Ren Y; Akyurek N; Schlette E; Rassidakis GZ; Medeiros LJ
Hum Pathol; 2006 Nov; 37(11):1407-13. PubMed ID: 16949641
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
33. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis.
Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
J Med Assoc Thai; 2002 May; 85(5):552-9. PubMed ID: 12188384
[TBL] [Abstract][Full Text] [Related]
34. Isolation of autologous antibodies to antigens-associated with Hodgkin's disease.
Dölken G; Löhr GW
Biomedicine; 1980; 33(5):163-7. PubMed ID: 7002227
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
36. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma.
Schneider EM; Torlakovic E; Stühler A; Diehl V; Tesch H; Giebel B
J Pathol; 2004 Dec; 204(5):538-45. PubMed ID: 15538755
[TBL] [Abstract][Full Text] [Related]
37. Non-specific normal immunosuppressive protein (Nip): purification and further biochemical characterization.
Gavison-Goren R; Nelken D
Immunology; 1983 Aug; 49(4):599-608. PubMed ID: 6192080
[TBL] [Abstract][Full Text] [Related]
38. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
[TBL] [Abstract][Full Text] [Related]
39. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Yoshiura K; Nakaoka T; Nishishita T; Sato K; Yamamoto A; Shimada S; Saida T; Kawakami Y; Takahashi TA; Fukuda H; Imajoh-Ohmi S; Oyaizu N; Yamashita N
Clin Cancer Res; 2005 Nov; 11(22):8201-7. PubMed ID: 16299253
[TBL] [Abstract][Full Text] [Related]
40. Immunoprecipitation of a Mr 64,000 glial tumor-associated antigen by monoclonal antibody 217c.
Luner SJ; de Vellis J
Cancer Res; 1986 Feb; 46(2):863-5. PubMed ID: 3940649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
